RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
RenovoRx, Inc.NASDAQ: RNXT
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$12.18M, compared with -$14.3M a year earlier.
Context
- Net debt amounted to 87.2% of total assets at the end of Q1 FY2026, down 2.1 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +14.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (6.81M) USD
- Year-over-year change
- +0.9%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.81M) | +0.9% |
| FY2024 | 2024-12-31 | (6.88M) | -486.2% |
| FY2023 | 2023-12-31 | (1.17M) | +73.3% |
| FY2022 | 2022-12-31 | (4.39M) | +71.1% |
| FY2021 | 2021-12-31 | (15.19M) | — |
Net Debt vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's Mar 2026 net debt of -$12.18M is the 4th highest of the 6 companies compared; the peer median is -$6.74M.
- Its year-over-year change of +14.8% is the 3rd highest of 6, against a peer median of -49.0%.
- Net debt amounts to 87.2% of total assets for RNXT, versus a peer median of 67.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $34.73M | -49.0% | -12.4% | 32.4% | |
| Mar 2026 | -$4.86M | +21.4% | — | 67.3% | |
| Mar 2026 | -$6.74M | -202.8% | — | 35.2% | |
| Mar 2026 | -$12.18M | +14.8% | — | 87.2% | |
| Mar 2026 | -$14.22M | +36.1% | — | 87.5% | |
| Mar 2026 | -$34.41M | -216.8% | — | 97.4% | |
| Peer median (excluding RNXT) | -$6.74M | -49.0% | -12.4% | 67.3% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.